Protocol summary
-
Study aim
-
Investigating the effects of curcumin-piperine combined with manual therapy on metabolic, inflammatory, oxidative stress markers, clinical symptoms, and electromyography in patients with frozen shoulder.
-
Design
-
A double-blind, phase 3, randomized, placebo-controlled trial with parallel groups.
Participants: 60 patients with frozen shoulder.
Randomization: 1:1 allocation via stratified block randomization (by age).
Blinding: Participants, therapists, and assessors are blinded.
-
Settings and conduct
-
Eligible patients, confirmed by an orthopedic specialist in Isfahan, will be enrolled after providing informed consent. All participants will undergo blood sampling before and after the two week intervention to compare the effects of curcumin piperine with manual therapy versus placebo plus manual therapy on biochemical markers. Supplement adherence will be monitored through returned pill counts at each visit.
-
Participants/Inclusion and exclusion criteria
-
Inclusion: Willing adults (20 to 65 years) with primary frozen shoulder (symptom duration: 1-12 months) diagnosed by an orthopedic specialist.
Exclusion: inability to adhere, serious adverse events, inflammatory diseases, recent use of curcumin, antiinflammatory supplements, smoking, and specific shoulder pathologies (rotator cuff tear, osteoarthritis, instability, referred cervical pain, or secondary frozen shoulder).
-
Intervention groups
-
Intervention: Daily curcumin-piperine capsule + manual therapy (3x/week) for 14 days.
Control: Daily placebo capsule + manual therapy (3x/week) for 14 days.
Manual Therapy Protocol: Each 30-minute session included soft tissue work, joint mobilizations, and stretching by trained physiotherapists.
-
Main outcome variables
-
Metabolic, inflammatory, oxidative stress markers and clinical symptoms.
General information
-
Reason for update
-
Typographical errors and omission of several important point
-
Acronym
-
-
IRCT registration information
-
IRCT registration number:
IRCT20121216011763N64
Registration date:
2024-06-15, 1403/03/26
Registration timing:
prospective
Last update:
2026-01-04, 1404/10/14
Update count:
2
-
Registration date
-
2024-06-15, 1403/03/26
-
Registrant information
-
-
Recruitment status
-
Recruitment complete
-
Funding source
-
-
Expected recruitment start date
-
2024-07-22, 1403/05/01
-
Expected recruitment end date
-
2025-03-10, 1403/12/20
-
Actual recruitment start date
-
empty
-
Actual recruitment end date
-
empty
-
Trial completion date
-
empty
-
Scientific title
-
The Effect of Combined Manual Therapy and Curcumin Piperine Supplementation on Metabolic Factors, Inflammatory Markers, Oxidative Stress, Clinical Symptoms, and Electromyography in Patients with Frozen Shoulder: A Randomized, Placebo-Controlled Clinical Trial.
-
Public title
-
The effects of curcumin piperine supplementation along with manual therapy on Frozen Shoulder Patients
-
Purpose
-
Treatment
-
Inclusion/Exclusion criteria
-
Inclusion criteria:
Agreement for participation in the study
Age of 20 to 65 years old
Diagnosis of frozen shoulder syndrome patients by an orthopedic specialist
Duration of symptoms between 1 and 12 months
Exclusion criteria:
Unwillingness or inability to provide informed consent or adhere to the study protocol.
Consumption of less than 80% of the prescribed supplement/placebo (verified by pill count).
Voluntary withdrawal from the study or being lost to follow-up
Occurrence of any allergic reaction or serious adverse event related to manual therapy or the supplement that makes continuation unsafe.
Significant worsening of pain or functional limitation requiring additional intervention (e.g., corticosteroid injection or surgery)
Systemic Inflammatory Diseases: Rheumatoid arthritis, ankylosing spondylitis, lupus, active gout, or other inflammatory arthropathies.
Neuromuscular Disorders: Severe peripheral neuropathy, cervical radiculopathy, thoracic outlet syndrome, or stroke with residual upper limb impairment affecting function.
Severe Uncontrolled Systemic Diseases: Renal or hepatic failure, active malignancy, bleeding disorders, active peptic ulcer disease, inflammatory bowel disease, cholelithiasis, or bile duct obstruction.
Use of any supplement containing curcumin, turmeric, or other potent herbal anti-inflammatory agents within the past 4 weeks.
Smoking
Current participation in any other clinical trial.
Other Shoulder Pathologies:* Diagnosis of impingement syndrome or full-thickness rotator cuff tear.* Symptomatic glenohumeral osteoarthritis.* Shoulder instability, prior dislocation, or history of surgery on the affected shoulder.* Cervical radiculopathy or other neurogenic causes of shoulder pain (confirmed by neurological examination).* Secondary frozen shoulder (due to diabetes, thyroid disorder, stroke, Parkinson's disease, trauma).
-
Age
-
From 20 years old to 65 years old
-
Gender
-
Male
-
Phase
-
3
-
Groups that have been masked
-
- Participant
- Investigator
- Outcome assessor
-
Sample size
-
Target sample size:
60
-
Randomization (investigator's opinion)
-
Randomized
-
Randomization description
-
Randomization will be done through the official website https://www.sealedenvelope.com/simple-randomiser/v1/list. The participants will be randomly (classified by randomized block method) in one of the two curcumin piperine supplement groups along with manual therapy and manual therapy plus placebo, as the control group. In order to distribute patients into intervention and control groups, first, people will be classified by age and divided using blocks of four. Randomization is done inside each block based on the random chain that will be extracted from the site.
-
Blinding (investigator's opinion)
-
Double blinded
-
Blinding description
-
In this study, participants, therapists, and assessors will be blinded to the receipt of curcumin-piperine or placebo.
-
Placebo
-
Used
-
Assignment
-
Parallel
-
Other design features
-
Ethics committees
1
-
Ethics committee
-
-
Approval date
-
2024-03-19, 1402/12/29
-
Ethics committee reference number
-
IR.MUI.PHANUT.REC.1402.089
Health conditions studied
1
-
Description of health condition studied
-
Frozen Shoulder
-
ICD-10 code
-
M75.0
-
ICD-10 code description
-
Adhesive capsulitis of shoulder
Primary outcomes
1
-
Description
-
Evaluation of shoulder function, range of motion, pain, and disability in patients with frozen shoulder.
-
Timepoint
-
At baseline and after 14 days
-
Method of measurement
-
Questionnaire
2
-
Description
-
Serum level of High sensitive C reactive protein
-
Timepoint
-
At baseline and after 14 days
-
Method of measurement
-
Enzyme-linked immunosorbent assay (ELISA) kits
3
-
Description
-
Total antioxidant capacity
-
Timepoint
-
At baseline and after 14 days
-
Method of measurement
-
Biochemical kit of KiaZist Co.
4
-
Description
-
Total oxidant status
-
Timepoint
-
At baseline and after 14 days
-
Method of measurement
-
Biochemical kit of KiaZist Co.
5
-
Description
-
Muscle nerve band
-
Timepoint
-
At baseline and after 14 days
-
Method of measurement
-
Electromyography
6
-
Description
-
Malondialdehyde
-
Timepoint
-
At baseline and after 14 days
-
Method of measurement
-
Biochemical kit of KiaZist Co.
7
-
Description
-
Serum concentration of glutathione
-
Timepoint
-
At baseline and after 14 days
-
Method of measurement
-
Biochemical kit of KiaZist Co.
8
-
Description
-
Superoxide dismutase activity
-
Timepoint
-
At baseline and after 14 days
-
Method of measurement
-
Biochemical kit of KiaZist Co.
9
-
Description
-
Serum level of vascular cell adhesion molecule-1
-
Timepoint
-
At baseline and after 14 days
-
Method of measurement
-
Enzyme-linked immunosorbent assay (ELISA) kits
10
-
Description
-
Erythrocyte sedimentation rate (ESR)
-
Timepoint
-
At baseline and after 14 days
-
Method of measurement
-
Biochemical kit of KiaZist Co.
11
-
Description
-
Serum level of IL-6
-
Timepoint
-
At baseline and after 14 days
-
Method of measurement
-
Enzyme-linked immunosorbent assay (ELISA) kits
12
-
Description
-
Serum level of TNF-a
-
Timepoint
-
At baseline and after 14 days
-
Method of measurement
-
Enzyme-linked immunosorbent assay (ELISA) kits
13
-
Description
-
Serum level of TGF
-
Timepoint
-
At baseline and after 14 days
-
Method of measurement
-
Enzyme-linked immunosorbent assay (ELISA) kits
14
-
Description
-
Serum level of IL-1β
-
Timepoint
-
At baseline and after 14 days
-
Method of measurement
-
Enzyme-linked immunosorbent assay (ELISA) kits
15
-
Description
-
Serum level of IL-8
-
Timepoint
-
At baseline and after 14 days
-
Method of measurement
-
Enzyme-linked immunosorbent assay (ELISA) kits
Secondary outcomes
1
-
Description
-
The average level of (total cholesterol, HDL, LDL, TG) in the intervention and control groups
-
Timepoint
-
Before and after intervention
-
Method of measurement
-
Kiazist biochemical kit
2
-
Description
-
The mean level of fasting blood sugar (FBS) among the intervention and control groups
-
Timepoint
-
Before and after intervention.
-
Method of measurement
-
Kiazist biochemical kit
3
-
Description
-
Quality of Life
-
Timepoint
-
Before and after intervention.
-
Method of measurement
-
Quality of life questionnaire
4
-
Description
-
Assessment of mental health status
-
Timepoint
-
Before and after intervention.
-
Method of measurement
-
Depression, Anxiety, and Stress Scale (DASS-21)
Intervention groups
1
-
Description
-
Daily intake of one capsule containing curcumin-piperine (with 500 mg of curcumin extract and 5 mg of piperine) alongside manual therapy (3 sessions per week) for 14 days. Manual Therapy Protocol: Manual therapy followed a fixed 30-minute protocol per session, including soft tissue techniques, specific joint mobilizations (Maitland), and passive stretching, delivered by trained physiotherapists.
-
Category
-
Treatment - Drugs
2
-
Description
-
Daily intake of one placebo capsule alongside manual therapy (3 sessions per week) for 14 days. Manual Therapy Protocol: Manual therapy followed a fixed 30-minute protocol per session, including soft tissue techniques, specific joint mobilizations (Maitland), and passive stretching, delivered by trained physiotherapists.
-
Category
-
Placebo
1
-
Sponsor
-
-
Grant name
-
Esfahan University of Medical Sciences, Research and Technology Vice-Chancellor
-
Grant code / Reference number
-
1402405
-
Is the source of funding the same sponsor organization/entity?
-
No
-
Title of funding source
-
Esfahan University of Medical Sciences, Research and Technology Vice-Chancellor
-
Proportion provided by this source
-
100
-
Public or private sector
-
Public
-
Domestic or foreign origin
-
Domestic
-
Category of foreign source of funding
-
empty
-
Country of origin
-
-
Type of organization providing the funding
-
Academic
Sharing plan
-
Deidentified Individual Participant Data Set (IPD)
-
Undecided - It is not yet known if there will be a plan to make this available
-
Study Protocol
-
Undecided - It is not yet known if there will be a plan to make this available
-
Statistical Analysis Plan
-
Undecided - It is not yet known if there will be a plan to make this available
-
Informed Consent Form
-
Undecided - It is not yet known if there will be a plan to make this available
-
Clinical Study Report
-
Undecided - It is not yet known if there will be a plan to make this available
-
Analytic Code
-
Undecided - It is not yet known if there will be a plan to make this available
-
Data Dictionary
-
Undecided - It is not yet known if there will be a plan to make this available